{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:55:37Z","timestamp":1760576137964,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.ejpb.2012.02.015","type":"journal-article","created":{"date-parts":[[2012,3,8]],"date-time":"2012-03-08T19:21:49Z","timestamp":1331234509000},"page":"334-338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["A novel liquefied gas based oral controlled release drug delivery system for liquid drug formulations"],"prefix":"10.1016","volume":"81","author":[{"given":"Dorota","family":"Haznar-Garbacz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Garbacz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friederike","family":"Eisen\u00e4cher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Weitschies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2012.02.015_b0005","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.addr.2005.01.025","article-title":"Magnetic marker monitoring: an application of biomagnetic measurement instrumentation and principles for the determination of the gastrointestinal behavior of magnetically marked solid dosage forms","volume":"57","author":"Weitschies","year":"2005","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.ejpb.2012.02.015_b0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0378-5173(02)00043-1","article-title":"Comparison of the mechanical destructive force in the small intestine of dog and human","volume":"37","author":"Kamba","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2012.02.015_b0015","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2982.2007.01061.x","article-title":"Gastric emptying of a non-digestible solid: assessment with simultaneous SmartPill pH and pressure capsule, antroduodenal manometry","volume":"20","author":"Cassilly","year":"2008","journal-title":"Gastric Emptying Scintigraphy. Neurogastroenterol. and Motil."},{"key":"10.1016\/j.ejpb.2012.02.015_b0020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.5414\/CPP44038","article-title":"Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union","volume":"44","author":"Wonnemann","year":"2006","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2012.02.015_b0025","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1517\/17425247.2010.527943","article-title":"A biorelevant dissolution stress test device \u2013 background and experiences","volume":"11","author":"Garbacz","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2012.02.015_b0030","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejpb.2009.07.002","article-title":"Oral osmotically driven system: 30years of development and clinical use","volume":"73","author":"Malaterre","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2012.02.015_b0035","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejps.2009.06.010","article-title":"Comparison of dissolution profiles obtained from nifedipine extended release once a day products using different dissolution test apparatuses","volume":"38","author":"Garbacz","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2012.02.015_b0040","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1185\/030079906X132613","article-title":"Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form","volume":"10","author":"Conley","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejpb.2012.02.015_b0045","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1208\/s12249-011-9689-8","article-title":"An oral controlled release drug delivery system for liquid and semisolid drug formulations","volume":"12","author":"Haznar-Garbacz","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2012.02.015_b0050","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/00005768-199803000-00020","article-title":"Telemetry pill measurement of core temperature in humans during active heating and cooling","volume":"30","author":"O\u2019Brien","year":"1998","journal-title":"Med. Sci. Sports Exerc."},{"key":"10.1016\/j.ejpb.2012.02.015_b0055","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1517\/14656566.9.2.285","article-title":"Oral valproic acid for epilepsy-long-term experience in therapy and side effects","volume":"9","author":"Gerstner","year":"2008","journal-title":"Expert Opin. Pharmather."},{"key":"10.1016\/j.ejpb.2012.02.015_b0060","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/1874467210902010095","article-title":"Biochemical, molecular and epigenetic mechanism of valproic acid neuroprotection","volume":"2","author":"Monti","year":"2009","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.ejpb.2012.02.015_b0065","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/479364","article-title":"Molecular and therapeutic potential and toxicity of valproic acid","author":"Chateauvieux","year":"2010","journal-title":"J. Biomed. Biotech."},{"issue":"5","key":"10.1016\/j.ejpb.2012.02.015_b0070","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.clineuro.2008.12.009","article-title":"Seizure control and side-effect profile after switching adult epileptic patients from standard to extended-release divalproex sodium","volume":"111","author":"Pierre-Louis","year":"2009","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.ejpb.2012.02.015_b0075","first-page":"789","article-title":"Valproic acid toxicity: overview and management","volume":"40","author":"Sztajnkrycer","year":"2002","journal-title":"Clin. Tox."},{"key":"10.1016\/j.ejpb.2012.02.015_b0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/FTD.0b013e3181c13a30","article-title":"Does valproic acid warrant therapeutic drug monitoring in bipolar affective disorder?","volume":"32","author":"Haymond","year":"2010","journal-title":"Ther. Drug. Monit."},{"key":"10.1016\/j.ejpb.2012.02.015_b0085","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0090-3019(97)00223-1","article-title":"Antiepileptic drug review: Part 1","volume":"49","author":"Winkler","year":"1998","journal-title":"Surg. Neurol."},{"key":"10.1016\/j.ejpb.2012.02.015_b0090","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.clinthera.2009.09.016","article-title":"A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions","volume":"9","author":"Marcel\u00edn-Jim\u00e9nez","year":"2009","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejpb.2012.02.015_b0095","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4088\/JCP.v60n0405","article-title":"The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study","volume":"60","author":"Zarate","year":"1999","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.ejpb.2012.02.015_b0100","unstructured":"Shuzo Ohe, Distilation, vapor pressure, vapour\u2013liquid equilibria. <www.s-ohe.com>."},{"key":"10.1016\/j.ejpb.2012.02.015_b0105","unstructured":"EMEA, Note for Guidance on Validation of Analytical Procedures: CPMP\/ICH\/381\/95."},{"key":"10.1016\/j.ejpb.2012.02.015_b0110","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11095-005-8476-1","article-title":"Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability\/bioequivalence studies","volume":"1","author":"Kalantzi","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2012.02.015_b0115","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2036.2005.02683.x","article-title":"Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging","volume":"22","author":"Schiller","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2012.02.015_b0120","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejps.2009.09.012","article-title":"Formulate-ability of ten compounds with different physicochemical profiles in SMEDDS","volume":"38","author":"Thi","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2012.02.015_b0125","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2174\/156720109789000519","article-title":"Self micro-emulsifying drug delivery system: formulation development and biopharmaceutical evaluation of lipophilic drugs","volume":"4","author":"Patel","year":"2009","journal-title":"Curr. Drug. Deliv."},{"key":"10.1016\/j.ejpb.2012.02.015_b0130","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ejps.2010.07.005","article-title":"Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes","volume":"41","author":"Christiansen","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2012.02.015_b0135","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/jps.22408","article-title":"Investigating the stability of the non-ionic surfactants tocopheryl polyethylene glycol succinate and sucrose laurate by HPLC-MS, DAD, and CAD","volume":"100","author":"Christiansen","year":"2011","journal-title":"J. Pharm. Sci."},{"issue":"Suppl 1","key":"10.1016\/j.ejpb.2012.02.015_b0140","first-page":"27","article-title":"Intestinal gas metabolism","volume":"3","author":"Montalto","year":"2009","journal-title":"Dig. Liver. Dis."},{"key":"10.1016\/j.ejpb.2012.02.015_b0145","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1172\/JCI115716","article-title":"Factors affecting hydrogen production and consumption by human fecal flora","volume":"89","author":"Strocchi","year":"1992","journal-title":"J. Clin. Invest."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641112000719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641112000719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:29:05Z","timestamp":1760545745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641112000719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0939641112000719"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2012.02.015","relation":{},"ISSN":["0939-6411"],"issn-type":[{"type":"print","value":"0939-6411"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel liquefied gas based oral controlled release drug delivery system for liquid drug formulations","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2012.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}